Exercise Versus DDAVP in Patients With Mild Hemophilia A

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

August 30, 2019

Study Completion Date

December 5, 2019

Conditions
Hemophilia A
Interventions
DRUG

DDAVP Inhalant Product

For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.

BEHAVIORAL

Exercise Intervention

For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.

Trial Locations (4)

43205

Nationwide Children's Hospital, Columbus

44308

Akron Children's Hospital, Akron

45404

Dayton Children's Hospital, Dayton

46260

Indiana Hemophilia and Thrombosis Center, Indianapolis

All Listed Sponsors
collaborator

The Hospital for Sick Children

OTHER

lead

Nationwide Children's Hospital

OTHER

NCT03379974 - Exercise Versus DDAVP in Patients With Mild Hemophilia A | Biotech Hunter | Biotech Hunter